Affinity Asset Advisors, LLC Editas Medicine, Inc. Transaction History
Affinity Asset Advisors, LLC
- $896 Million
- Q1 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 100,000 shares of EDIT stock, worth $221,000. This represents 1.04% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$221,000% of portfolio
1.04%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding EDIT
# of Institutions
224Shares Held
48.2MCall Options Held
436KPut Options Held
324K-
Black Rock Inc. New York, NY7.78MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.47MShares$16.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.66MShares$5.88 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.6MShares$5.75 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$4.34 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $152M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...